ସାଟ୍ରାଲିଜୁମାବ

ସାଟ୍ରାଲିଜୁମାବ
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	interleukin 6 receptor
Clinical data
Trade names	Enspryng
Synonyms	SA-237, sapelizumab, satralizumab-mwge
AHFS/Drugs.com	monograph
data	US DailyMed: Satralizumab;
Pregnancy; category	AU: C ; ;
Routes of; administration	Subcutaneous
Legal status
Legal status	CA: Schedule D ; US: ℞-only ; ℞ (Prescription only);
Chemical and physical data
Formula	C6340H9776N1684O2022S46
Molar mass	୧,୪୩,୪୧୬.୪୭ g·mol−1

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Satralizumab

ସାଟ୍ରାଲିଜୁମାବ (ଇଂରାଜୀ ଭାଷାରେ Satralizumab),ଏନ୍ସପ୍ରିଙ୍ଗ ଏହାର ବେପାର ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଆକ୍ୱାପୋରିନ 4 (AQP4) ବିରୁଦ୍ଧରେ ଆଣ୍ଟିବଡି ଥିବା ନ୍ୟୁରୋମାଇଲିଟିସ୍ ଅପ୍ଟିକା ସ୍ପେକ୍ଟ୍ରମ୍ (NMOSD) ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୪] ଚର୍ମ ତଳେ ଇଞ୍ଜେକସନ ଆକାରରେ ଏହା ଦିଆଯାଏ ।

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡବିନ୍ଧା, ଗଣ୍ଠି ଯନ୍ତ୍ରଣା, ଉଚ୍ଚ ରକ୍ତ ଲିପିଡ ସ୍ତର, ଇଞ୍ଜେକସନ ସ୍ଥାନରେ ଯନ୍ତ୍ରଣା ଏବଂ ସ୍ୱଳ୍ପ ଶ୍ୱେତ ରକ୍ତ କଣିକା ହୋଇପାରେ ।^[୫] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସଂକ୍ରମଣ, ଯକୃତ ସମସ୍ୟା, ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା ଏବଂ ଲୁକ୍କାୟିତ ଯକ୍ଷ୍ମା ସକ୍ରିୟ ହୋଇପାରେ । ^[୪] ଏହା ଏକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହା ଇଣ୍ଟରଲିଉକିନ୍ -୬କୁ (ଆଇଏଲ୍ -6) ଅବରୋଧ କରିଥାଏ ଏବଂ ଏହିପରି ଏକ୍ୟୁପି୪ (AQP4) ବିରୁଦ୍ଧରେ ଆଣ୍ଟିବାୟୋଟିକ୍ ହ୍ରାସ କରେ |

୨୦୨୦ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୨୧ରେ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ସାଟ୍ରିଲିଜୁମାବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୪] ^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହାର ମୂଲ୍ୟ ୨୦୨୧ ସୁଦ୍ଧା ପ୍ରାୟ ୧୫,୩୦୦ ଡଲାର ଥିଲା । ^[୬] ୨୦୨୧ ସୁଦ୍ଧା ବ୍ରିଟେନରେ ଏହା ଉପଲବ୍ଧ ହୋଇନଥିଲା ।^[୭]

ଆଧାର[ସମ୍ପାଦନା]

↑ "Satralizumab Product information". Drug Product Database. Health Canada. Archived from the original on 29 August 2021. Retrieved 17 August 2020.
↑ "Enspryng- satralizumab injection, solution". DailyMed. 24 August 2020. Archived from the original on 27 February 2021. Retrieved 24 September 2020.
↑ "FDA Approves Treatment for Rare Disease Affecting Optic Nerves, Spinal Cord". U.S. Food and Drug Administration (FDA). 17 August 2020. Archived from the original on 23 August 2020. Retrieved 17 August 2020. This article incorporates text from this source, which is in the public domain.
↑ ^୪.୦ ^୪.୧ ^୪.୨ "Satralizumab-mwge Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 11 October 2021.
↑ ^୫.୦ ^୫.୧ "Enspryng". Archived from the original on 13 August 2021. Retrieved 11 October 2021.
↑ "Enspryng Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 11 October 2021.
↑ "Satralizumab". SPS - Specialist Pharmacy Service. 1 December 2016. Archived from the original on 12 October 2021. Retrieved 11 October 2021.

[1] "Satralizumab Product information". Drug Product Database. Health Canada. Archived from the original on 29 August 2021. Retrieved 17 August 2020.

[Enspryng_FDA_label-2] "Enspryng- satralizumab injection, solution". DailyMed. 24 August 2020. Archived from the original on 27 February 2021. Retrieved 24 September 2020.

[FDA_PR-3] "FDA Approves Treatment for Rare Disease Affecting Optic Nerves, Spinal Cord". U.S. Food and Drug Administration (FDA). 17 August 2020. Archived from the original on 23 August 2020. Retrieved 17 August 2020. This article incorporates text from this source, which is in the public domain.

[AHFS2021-4] ୪.୦ ^୪.୧ ^୪.୨ "Satralizumab-mwge Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 11 October 2021.

[EPAR2021-5] ୫.୦ ^୫.୧ "Enspryng". Archived from the original on 13 August 2021. Retrieved 11 October 2021.

[6] "Enspryng Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 11 October 2021.

[SP2021-7] "Satralizumab". SPS - Specialist Pharmacy Service. 1 December 2016. Archived from the original on 12 October 2021. Retrieved 11 October 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]